Source:
Reuters18 May 2010, 1902 hrs IST,REUTERS
NEW YORK: Drugmaker Pfizer Inc will cut 6,000, or 18 percent, of jobs at its 78 manufacturing plants over the next five years as it consolidates operations following last year's purchase of smaller rival Wyeth. The world's biggest drugmaker said it would cease operations at eight plants in Ireland, Puerto Rico and the United States by late 2015 and reduce activities at six factories in those countries, Germany and Britain. Pfizer had 40 manufacturing sites before acquiring more than three dozen Wyeth facilities in the October merger.
The affected plants make conventional pills, injectable medicines, biotech drugs and consumer healthcare products. Pfizer will wind down their operations over the next 18 months to five years, depending on business considerations such as the time required to transfer product manufacturing. The company had said in November that it would close six research sites and trim jobs in the United States and Britain as part of its ongoing absorption of Wyeth.
"We have a complex network of manufacturing plants, with excess capacity that is not good for costs," Nat Ricciardi, Pfizer's president of manufacturing, said in an interview. Pfizer can be more competitive, both in its operations and drug pricing, by streamlining its plants and improving their processes, Ricciardi said. "It's not disproportionately Wyeth," Ricciardi said, adding that many legacy Pfizer plants and employees are on the target list.
One of the biggest incentives for companies to merge is the ability to cut overlapping operations and employees, creating huge cost savings. Pfizer is counting on savings from the Wyeth merger to help offset expected plunging sales of its $12 billion-a-year Lipitor cholesterol fighter, which begins facing generic competition late next year. The 14 plants slated to cease operations or downsize are among Pfizer's 40 main sites for making prescription drugs. The company plans by June to make recommendations for facilities that make animal-health products and later this year will evaluate those that make drugs in emerging markets or nutritional products.
Read more:
http://economictimes.indiatimes.com/news/international-business/Pfizer-to-close-more-plants-cut-6000-jobs/articleshow/5945734.cms